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Abstract: Altered lipid metabolism has been shown to be of major importance in a range of 
metabolic diseases, with particular importance in cardiovascular disease (CVD). As a key metabolic 
product, altered lipoprotein(a) (Lp(a)) levels may be associated with adverse clinical outcomes in 
high-risk cardiovascular patients undergoing cardiac surgery. We aimed to investigate the impact 
of the important metabolite Lp(a) on complications and clinical outcomes in high-risk patients. A 
prospective observational cohort study was performed. Data were derived from the Bern 
Perioperative Biobank (ClinicalTrials.gov NCT04767685), and included 192 adult patients 
undergoing elective cardiac surgery. Blood samples were collected at 24 h preoperatively, before 
induction of general anaesthesia, upon weaning from cardiopulmonary bypass (CPB), and the first 
morning after surgery. Clinical endpoints included stroke, myocardial infarction, and mortality 
within 30 days after surgery or within 1 year. Patients were grouped according to their preoperative 
Lp(a) levels: < 30 mg/dL (n = 121; 63%) or > 30 mg/dL (n = 71, 37%). The groups with increased vs. 
normal Lp(a) levels were comparable with regard to preoperative demographics and comorbidities. 
Median age was 67 years (interquartile range (IQR) 60.0, 73.0), with median body mass index (BMI) 
of 23.1 kg/m2 (23.7, 30.4), and the majority of patients being males (75.5%). Over the observational 
interval, Lp(a) levels decreased in all types of cardiac surgery after CPB (mean decline of 
approximately −5 mg/dL). While Lp(a) levels decreased in all patients following CPB, this 
observation was considerably pronounced in patients undergoing deep hypothermic circulatory 
arrest (DHCA) (decrease to preoperative Lp(a) levels by −35% (95% CI −68, −1.7), p = 0.039). 
Increased Lp(a) levels were neither associated with increased rates of perioperative stroke or major 
adverse events in patients undergoing cardiac surgery, nor with overall mortality in the 
perioperative period, or at one year after surgery. Other than for cohorts in neurology and 
cardiology, elevated Lp(a) might not be a risk factor for perioperative events in cardiac surgery. 
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Elevated lipoprotein(a) (Lp(a)) levels have previously been shown to be an 
independent cardiovascular (CV) risk factor and an acute-phase reactant involved in the 
repair of tissue injury—most likely via angiogenesis [1–3]. Lp(a) levels are genetically 
determined, and are associated with elevated risk of CV disease and calcified aortic 
stenosis [4–6]. The alteration of circulating Lp(a), which has the ability to modify Lp(a) 
functions, is an important part of Lp(a) metabolism. There are currently limited 
therapeutic medications that selectively target increased Lp(a); however, a variety of 
potential treatments are being investigated [7]. Recently, a therapeutic approach with 
antisense oligonucleotides (APO(a)LRx) was shown to potently and selectively reduce 
Lp(a) levels [8]. 
A recent meta-analysis including over 29,000 patients demonstrated an almost linear 
positive correlation between Lp(a) levels and CV outcomes [9]. The current evidence 
suggests that the risk of CV disease is increased by over 40% in patients with Lp(a) levels 
of 30 mg/dLor greater, compared with patients with levels < 15 mg/dl, independently of 
low-density levels of cholesterol (LDL-C) and other risk factors [10,11]. 
Originally, a cutoff concentration of 30  mg/dLwas defined, above which the risk of 
myocardial infarction increases [12,13]. Elevated Lp(a) may also lead to acute 
destabilisation of pre-existing but quiescent atherosclerotic plaques, which may induce 
acute myocardial infarction and stroke [9,14,15]. Lp(a) has been proven to be associated 
with coronary severity and clinical outcomes in patients with various types of coronary 
artery disease (CAD), such as stable CAD or acute myocardial infarction (AMI) [5,16]. In 
a large cohort of > 6000 patients studied by Xu et al., Lp(a) was identified as a strong risk 
factor for poor prognosis over the long term, and can aid in risk stratification in patients 
with triple-vessel disease [17].  
However, to the best of our knowledge, there are currently no studies reporting the 
impact of preoperative elevated Lp(a) on perioperative outcomes after coronary artery 
bypass grafting or valvular and aortic cardiac surgery. 
In this prospective study using multiple timed blood samples, we examined the role 
of Lp(a) changes in patients during and after different types of cardiac surgery, and 
related the data to clinical complications and outcomes. Given the strong collinearity and 
complex interplay of cause and effect of Lp(a) and lipids, and current therapeutic 
approaches to selectively target Lp(a), we specifically focused on Lp(a) only. 
2. Materials and Methods 
2.1. Cohort Description  
This prospective observational cohort study from the Bern Perioperative Biobank 
(ClinicalTrials.gov NCT04767685) included 192 adult patients who underwent cardiac 
surgery between January 2019 and December 2019 at our institution (Figure 1). No formal 
sample size was selected, since this was the first such systematic data collection of Lp(a) 
and, thus, no reference values were available to estimate possible effect sizes. 
Patients were required to provide prior informed consent. Patients who underwent 
emergent surgeries (defined as < 6 h recruitment time between hospital admission and 
surgery), women with suspected or confirmed pregnancy, and patients who were unable 
to consent were excluded. Cardiac surgical procedures included coronary artery bypass 
grafting (CABG) and replacement or repair of the aortic (AVR), mitral (MVR), and 
tricuspid (TVR) valves, as well as surgery of the ascending aorta or aortic arch. All patients 
received median sternotomy and cardiopulmonary bypass, either with conventional 
extracorporeal circulation circuits (CECC) or minimally invasive extracorporeal 
circulation circuits (MiECC). 




Figure 1. Flow diagram displaying the inclusion of patients. Only non-emergency patients 
undergoing cardiac surgery with the use of cardiopulmonary bypass (CPB) were included. The 
inclusion was limited by the operating hours of the institutional biobank, accepting blood samples 
between 8 a.m. and 4:30 p.m. 
2.2. Primary and Secondary Outcomes  
The primary outcome was the association of preoperative Lp(a) values (dichotomised 
according to the threshold of 30 mg/dL) with the incidence of postoperative stroke, 30-
day all-cause mortality, and overall survival during the one-year postoperative follow-up 
period. Secondary endpoints included the association of preoperative Lp(a) values with 
the postoperative hospitalisation duration, the occurrence of renal complications and the 
need for renal replacement therapy, the need for postoperative atrial fibrillation (AFIB), 
the incidence of postoperative myocardial infarction (MI), and the need for re-exploration 
for bleeding. Peri- and postoperative endpoints were defined according to the guidelines 
of Akins et al. [18]. The study population, covariates, endpoints, and laboratory analyses 
are described in the Supplementary Materials.  
Given the different definitions of myocardial infarction amongst guidelines for 
cardiac surgeons and cardiologists, we manually screened all patient records for clinical 
signs of acute coronary syndromes during their stay. Specifically, we checked for creatine 
kinase-MB (CK-MB) levels (3x upper normal limit (UNL)) and respective clinical 
symptoms with corresponding ST elevation in the ECG, including elevated troponin 
levels and/or postoperative diagnostic or therapeutic interventions in the cardiac 
catheterisation lab. Approval by the local ethics committee was obtained for sample 
collection (KEK Nr. 2018-01272) and for data analysis (KEK Nr. 2019-2000). Ethical 
guidelines for publishing were adhered to [19]. 
2.3. Collection and Analysis of Blood Samples  
Blood samples (heparin) were collected at 24 h preoperatively (baseline), before 
induction of general anaesthesia (preoperative), upon weaning from cardiopulmonary 
bypass (CPB) (intraoperative), and 24 h after surgery (postoperative), and stored at the 
Bern Liquid Biobank. Biochemical markers were analysed at the Institute for Clinical 
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Chemistry and Laboratory Medicine, Rostock University Medicine, Rostock, Germany. 
An automated standard biochemical analyser was used to measure the concentrations of 
relevant indicators, including LDL-C, total cholesterol (TC), high-density lipoprotein 
cholesterol (HDL-C), and Lp(a). Lp(a) levels were assayed via an immunoturbidimetric 
method according to the manufacturer’s instructions, using the latex turbidimetric 
method (LASAY Lp(a) auto; SHIMA Laboratories Co. Ltd, Tokyo, Japan) [20]. Patients 
were followed up until postoperative day 30, and all-cause mortality was recorded at one 
year after surgery.  
After recruitment for the Biobank study, all relevant pre-, peri-, and postoperative 
data for each patient were collected from electronic patient charts (Dendrite Clinical Sys-
tems Ltd., Henley on-Thames, UK). Information on all-cause mortality was obtained from 
the national records or from internal hospital records. Logistic EuroSCORE and Eu-
roSCORE II were calculated to assess the presumed risk of 30-day all-cause mortality. The 
logistic EuroSCORE and EuroSCORE II range from 0.88 or 0.5, respectively, to < 100, rep-
resenting the percentage risk of perioperative death [21]. A manual check of the clinical 
records revealed no additional acute coronary syndromes and/or diagnostic or therapeu-
tic interventions in the cardiac catheterisation lab. 
2.4. Statistical Analysis 
Continuous variables were presented as means and standard deviations in the case 
of normally distributed variables, and as medians and interquartile ranges (IQRs) in other 
cases. Continuous distributions were examined using the Shapiro–Wilk test for normality 
and QQ plots. Categorical variables were presented as counts and percentages. The 
amount and distribution of missing values are provided in the Supplementary Materials. 
The distribution of preoperative Lp(a) levels and their changes over time are also indi-
cated in the Supplementary Materials. 
For categorical variables, group comparisons between patient groups with high pre-
operative Lp(a) values (defined as above the threshold of 30 mg/dL) and low Lp(a) values 
(below 30 mg/dL) were based on a permutation chi-squared test (with 2000 permutations) 
in cases of cell values lower than 5, and on Fisher’s exact test otherwise [13]. For continu-
ous variables, the group comparisons were based on Student’s t-test for normally distrib-
uted variables, and on the Wilcoxon rank-sum test otherwise. Lp(a) values at different 
timepoints were presented using geometric means and associated 95% confidence inter-
vals. Bivariate associations of the change in Lp(a) from preoperative to postoperative val-
ues for each surgical characteristic (i.e., bypass time) were illustrated using boxplots (in 
the case of categorical variables) and with locally estimated scatterplot smoothing (LO-
ESS). 
As there were multiple primary outcomes, we adjusted the p-values using the Benja-
mini–Hochberg method, and presented both unadjusted and adjusted values. As the sec-
ondary analyses were exploratory in nature, no p-value adjustment was performed. We 
further studied the ratio of postoperative to preoperative Lp(a) values, and the association 
of each surgical characteristic with this ratio was computed with a multivariable linear 
regression model. For this part of the analysis, we excluded patients whose Lp(a) values 
were below the measurement threshold (< 2 mg/dL), as they all featured the same (default) 
Lp(a) value (1.98 mg/dL). The fit of the regression model was assessed via examination of 
the relationship between the model’s residual values and the fitted values. Multicolline-
arity across the surgical characteristics was studied by computing the variance inflation 
factor (VIF) for each predictor. For sensitivity analysis, the surgical characteristic with the 
highest VIF score (bypass time) was excluded from the model, and the corresponding 
model fit is presented in the Supplementary Materials (Table S2).  
A p-value < 0.05 was considered statistically significant. All computations were per-
formed using the R software environment (R version 4.0.2; R Core Team (2020). R: A lan-
guage and environment for statistical computing; R Foundation for Statistical Computing, 
Vienna, Austria; URL: https://www.R-project.org/, last accessed on 19th October 2021. 




Patient characteristics, procedural data, and outcomes are shown in Tables 1–4. Miss-
ing data are presented in the Supplementary Material (Table S1). 
A total of 192 patients were included in the study (Table 1). Patients were grouped 
according to their preoperative Lp(a) levels: those with low Lp(a)-levels of < 30 mg/dL (n 
= 121; 63%), and those with high Lp(a)-levels of > 30 mg/dL (n = 71, 37%). Groups were 
comparable in terms of preoperative demographics and comorbidities, with no significant 
differences for any variables. The median age was 67 years (interquartile range 60.0, 73.0), 
with a median body mass index (BMI) of 26.1 kg/m2 (23.7, 30.4), and the majority of pa-
tients were male (75.5%). The most common comorbidity was arterial hypertension, pre-
sent in 68.4% of patients, followed by dyslipidaemia (58.1%) and diabetes (18.2%). While 
levels of preoperative lipoproteins were comparable between groups, the triglycerides 
were significantly higher in patients with lower Lp(a) levels (1.40 mmol/L (1.04, 1.98) vs. 
1.16 mmol/L (0.92, 1.63), p = 0.027). Significant carotid disease was present in 7.3% of pa-
tients. The median ejection fraction (EF) was 60.0% (55.0, 65.0), and the majority of patients 
had a low risk of perioperative mortality, with a median EUROSCORE II of 1.73 (0.9, 2.9) 
and logistic EUROSCORE of 4.65 (2.3, 8.0). The most common procedures included AVR 
(44.8%) and CABG (40.1%), followed by MVR (23.4%) and ascending aortic replacement 
(19.8%). Accordingly, the MiECC circuit was used only in isolated CABG cases (22.4%). 
The two groups had similar CPB and aortic cross-clamp times (104 min (80.0, 132.0) and 
68.5 min (52.0, 91.8), respectively), but overall surgery time was significantly longer in the 
group with higher Lp(a) levels (223 min (188.0, 269.0), vs. 248 min (208.0, 287.0), p = 0.030). 
Of note, we found no statistically difference gender distribution in the low- and high-
Lp(a) groups (p = 0.461).  
Table 1. Baseline characteristics grouped by preoperative Lp(a). 
 All patients 
Low Lp(a)  
(< 30 mg/dL) 
High Lp(a)  
(≥ 30 mg/dL) 
P 





66.0 (60.0;73.0) 69.0 (61.0;74.5) 0.246 








26.7 (23.8;30.4) 25.4 (23.4;29.7  0.206 
Sex (Male) 145 (75.5%) 94 (77.7%) 51 (71.8%) 0.461 
Comorbidities 
Diabetes (Yes) 35 (18.2%) 25 (20.7%) 10 (14.1%) 0.344 
Diabetes on insulin    0.667 
No 24 (68.6%)  18 (72.0%)  6 (60.0%)  
Yes 11 (31.4%) 7 (28.0%) 4 (40.0%)  
Hypertension† (Yes) 130 (68.4%) 79 (66.4%) 51 (71.8%) 0.535 
Dyslipidaemia† (Yes) 111 (58.1%) 70 (58.3%) 41 (57.7%) 1.000 
Nicotine†    0.173 
Former smoker 49 (26.1%)  36 (30.0%) 13 (19.1%)  
Non-smoker 97 (51.6%) 61 (50.8%) 36 (52.9%)  
Smoker 42 (22.3%) 23 (19.2%) 19 (27.9%)  
Adipositas (Yes) 52 (27.1%) 34 (28.1%) 18 (25.4%) 0.806 
Preoperative renal disease 
(Yes) 
43 (22.4%) 24 (19.8%) 19 (26.8%) 0.351 
Peripheral vascular disease†    0.528 
No 167 (93.8%) 107 (94.7%) 60 (92.3%)  
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 All patients 
Low Lp(a)  
(< 30 mg/dL) 
High Lp(a)  
(≥ 30 mg/dL) 
P 
 N = 192 N = 121 N = 71  
Stage 1 4 (2.25%) 3 (2.65%) 1 (1.54%)  
Stage 2 4 (2.25%) 1 (0.88%) 3 (4.62%)  
Stage 3 1 (0.56%) 1 (0.88%) 0 (0.00%)  
Stage 4 2 (1.12%) 1 (0.88%) 1 (1.54%)  
Carotid disease†    0.226 
< 50% 1 (0.58%) 1 (0.94%) 0 (0.00%)  
> 90% 3 (1.75%) 1 (0.94%) 2 (3.08%)  
50-69%, 9 (5.26%) 5 (4.72%) 4 (6.15%)  
70-89% 2 (1.17%) 0 (0.00%) 2 (3.08%)  
no 156 (91.2%) 99 (93.4%) 57 (87.7%)  
Myocardial infarction†    0.832 
No MI 171 (89.5%) 106 (88.3%) 65 (91.5%)  
MI 0-7 days before operation 3 (1.57%) 2 (1.67%) 1 (1.41%)  
MI 8-90 days before operation 8 (4.19%) 5 (4.17%) 3 (4.23%)  
MI > 90 days before operation 9 (4.71%) 7 (5.83%) 2 (2.82%)  
COPD† (Yes) 23 (12.1%) 17 (14.3%) 6 (8.45%) 0.336 
NYHA†    0.879 
1 60 (31.4%) 37 (30.8%) 23 (32.4%)  
2 90 (47.1%) 59 (49.2%) 31 (43.7%)  
3 38 (19.9%) 22 (18.3%) 16 (22.5%)  
4 3 (1.57%) 2 (1.67%) 1 (1.41%)  
CCS†    0.950 
0 118 (62.4%) 72 (61.0%) 46 (64.8%)  
1 34 (18.0%) 22 (18.6%) 12 (16.9%)  
2 25 (13.2%) 17 (14.4%) 8 (11.3%)  
3 9 (4.76%) 5 (4.24%) 4 (5.63%)  












4.65 (2.44;7.41) 4.92 (2.08;10.9) 0.667 
Valve type 
Aortic valve (Yes) 86 (44.8%) 55 (45.5%) 31 (43.7%) 0.928 
Mitral valve (Yes) 45 (23.4%) 30 (24.8%) 15 (21.1%) 0.687 
Tricuspid valve (Yes) 17 (8.85%) 12 (9.92%) 5 (7.04%) 0.679 
Coronary artery bypass (Yes) 77 (40.1%) 42 (34.7%) 35 (49.3%) 0.066 
Ascending aortic (Yes) 38 (19.8%) 23 (19.0%) 15 (21.1%) 0.867 
Aortic arch (Yes) 11 (5.73%) 7 (5.79%) 4 (5.63%) 1.000 
Preoperative Lipoproteins 




1.08 (0.92;1.36) 1.16 (0.92;1.34) 0.609 
LDL cholesterol (mmol/L) 
2.68 
(2.14;3.40) 
2.72 (2.30;3.41) 2.47 (2.00;3.26) 0.096 
Quotient overall (.) 
2.50 
(1.80;3.20) 








7.00 (3.00;14.0) 59.0 (44.0;91.5) < 0.001 
Procedural characteristics 
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 All patients 
Low Lp(a)  
(< 30 mg/dL) 
High Lp(a)  
(≥ 30 mg/dL) 
P 
 N = 192 N = 121 N = 71  
ECC or MiECC    0.566 
ECC 149 (77.6%) 96 (79.3%) 53 (74.6%)  
MiECC 43 (22.4%) 25 (20.7%) 18 (25.4%)  
Bypass time (min) 104 (80.0;132) 103 (78.0;130) 109 (83.0;136) 0.572 
Aortic cross-clamping (min) 
68.5 
(52.0;91.8) 
68.0 (51.0;90.0) 70.0 (53.5;95.5) 0.774 
Lowest body temperature (°C) 
33.2 
(32.1;33.8) 
33.3 (32.0;33.9) 33.2 (32.3;33.8) 0.998 
Deep hypothermic cardiac ar-
rest† (Yes) 
19 (9.95%) 13 (10.7%) 6 (8.57%) 0.816 
Operation duration (min) 234 (195;276) 223 (188;269) 248 (208;287) 0.030 
† Includes missing data. 
3.1. Lp(a) Subanalysis of Primary and Secondary Outcomes 
Overall, death occurred in only two patients (1.04%, 95% CI: 0.1%–3.7%) within 30 
days after surgery (1.65% (95% CI: 0.2%–5.8%) in patients with low Lp(a) levels, vs. 0% 
(95% CI: 0.0%–5.1%) in those with high Lp(a) levels, p = 0.729), and in only seven patients 
at 1 year following surgery (4.2% (95% CI: 1.4%–9.5%) vs. 2.99% (95% CI: 0.4%–10.4%), p 
= 0.729). The finding of no significant association between the Lp(a) group and the primary 
outcomes was not sensitive with respect to the group threshold of 30 mg/dL (Supplemen-
tary Materials). 
Stroke rates were comparable between groups (4.2% (95% CI: 1.4%–9.5%) in patients 
with lower Lp(a) levels, vs. 8.45% (95% CI: 3.2%–17.5%) in those with higher Lp(a) levels, 
p = 0.729) (Table 2). With respect to all secondary outcomes, we observed no difference in 
secondary endpoints. Median hospitalisation duration was 7 days in both groups (6.0, 9.0) 
(p = 0.367). The most common complication was postoperative AFIB (24.0% (95% CI: 
16.7%–32.6%) vs. 21.1% (95% CI: 12.3%–32.4%), p = 0.784), and postoperative MI occurred 
in only six patients (3.1%, 95% CI: 0.9%–8.3%) (Table 3). 
Table 2. Primary outcomes. 
 All patients 
Low Lp(a)  
(< 30 mg/dL) 
High Lp(a)  
(≥ 30 mg/dL) 
P P-adj* 
 N = 192 N = 121 N = 71   
Postoperative stroke†    0.335 0.729 
No 179 (94.2%) 114 (95.8%) 65 (91.5%)    
Yes 11 (5.79%) 5 (4.20%) 6 (8.45%)    
30-day mortality    0.530 0.729 
Died 2 (1.04%) 2 (1.65%) 0 (0.00%)   
Survived 190 (99.0%) 119 (98.3%) 1 (100%)   
1-Year follow-up‡    0.729 0.729 
Alive 179 (96.2%) 114 (95.8%) 65 (97.0%)   
Deceased 7 (3.76%) 5 (4.20%) 2 (2.99%)   
† 2 missing values; ‡ 6 missing values; * Benjamini–Hochberg adjustment for multiple comparisons. 
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Table 3. Secondary outcomes. 
 All patients 
Low Lp(a)  
(< 30 mg/dL) 
High Lp(a)  
(≥ 30 mg/dL) 
P 
 N = 192 N = 121 N = 71  
Length of postoperative hospital 
stay (days) 
7.00 (6.00;9.00) 7.00 (6.00;9.00) 7.00 (6.00;9.00) 0.367 
Renal complications    0.370 
No 191 (99.5%) 121 (100%) 70 (98.6%)  
Yes 1 (0.52%) 0 (0.00%) 1 (1.41%)  
Renal replacement therapy    > 0.99 
No 191 (99.5%) 120 (99.2%) 71 (100%)  
Yes 1 (0.52%) 1 (0.83%) 0 (0.00%)  
Postoperative atrial fibrillation    0.784 
No 148 (77.1%) 92 (76.0%) 56 (78.9%)  
Yes 44 (22.9%) 29 (24.0%) 15 (21.1%)  
Myocardial infarction    > 0.99 
No 186 (96.9%) 117 (96.7%) 69 (97.2%)  
Yes 6 (3.12%) 4 (3.31%) 2 (2.82%)  
Re-exploration for bleeding    > 0.99 
No 188 (97.9%) 118 (97.5%) 70 (98.6%)  
Yes 4 (2.08%) 3 (2.48%) 1 (1.41%)  
Table 4. Multivariable linear regression of the ratio of postoperative Lp(a) values to preoperative 
Lp(a) values (%) relative to several surgical characteristics. Note that Lp(a) values below the meas-
urement accuracy (< 2 mg/dl) were excluded from the analysis. 
 Coefficient 95% CI1 P 
ECC or MiECC    
ECC    
MiECC 9.8 −5.6, 25 0.21 
Bypass time (hours) −5.1 −29, 19 0.67 
Aortic cross clamping (hours) 4.8 −18, 28 0.68 
Lowest body temperature (°C) −4.0 −8.0, -0.06 0.046 
Deep hypothermic cardiac arrest    
No    
Yes −35 −68, −1.7 0.039 
Operation duration (hours) −11 −20, −1.7 0.020 
1CI: confidence interval. 
3.2. Lp(a) Subanalysis of Pre-, Intra-, and Postoperative Levels Stratified by Perioperative 
Covariates 
Lp(a) levels decreased in all types of cardiac surgery after weaning off CPB (median 
drop of -4 mg/dL (95% CI −7–−1), p = 0.004), although this drop was more significant in 
patients with preoperatively higher levels of Lp(a) of over 30 mg/dL (median drop of −21 
mg/dL (95% CI −29–-14), p < 0.001) (Figure 2). In all groups, Lp(a) levels had residually 
recovered by 24 h after surgery; however, a less significant increase was observed in the 
high-Lp(a) group, but postoperative Lp(a) values in this group were not significantly 
lower than preoperative values (median difference −4 mg/dL (95% CI −10–2), p = 0.172).  




Figure 2. Time series of Lp(a): geometric means and their associated 95% confidence intervals are 
shown for all patients (in black), high-Lp(a) patients (preoperative Lp(a) ≥ 30 mg/dl; in red), and 
low-Lp(a) patients (preoperative Lp(a) < 30 mg/dl; in blue). 
While Lp(a) levels were decreased in all patients following CPB, this decrease was 
less consistent in patients with lower Lp(a) levels, and was most evident and significant 
in patients with deep hypothermic circulatory arrest (DHCA) (decrease in preoperative 
Lp(a) levels of −35% (95% CI -68, -1.7), p = 0.039), followed by operation duration (for each 
additional hour of surgery, preoperative Lp(a) values decreased by −11% (95% CI -20%, -
1.7%), p = 0.020) and lower body temperature (for each degree of body temperature in-
crease, the preoperative Lp(a) values decreased by −4.0% (95% CI -8.0%, -0.06%), p = 0.046) 
(Table 4). A sensitivity analysis excluding possible collinear predictors is presented inup-
plementary Table S3. There were no significant correlations observed between duration 
of CPB support, aortic cross-clamp time, and perfusion system used (ECC vs. MiECC), as 
illustrated in Figure 3. 




Figure 3. Bivariate associations of surgical characteristics with the change in Lp(a) from preopera-
tive to postoperative values. Boxplots are shown for categorical variables (A,B), and locally esti-
mated scatterplot smoothing (LOESS) estimates and their associated 95% confidence intervals (grey 
shading) are depicted for continuous variables (C–F). Each dot represents the change in Lp(a) for an 
individual patient. 
4. Discussion 
In the present analysis, we observed no influence of Lp(a) levels on perioperative 
stroke and/or major adverse cardiac and cerebrovascular event (MACCE) rates in patients 
after coronary, valvular, or aortic surgery. No difference in overall mortality was observed 
in the perioperative period, nor at one year after surgery. 
Perioperative stroke is a severe complication after cardiac surgery, and has the great-
est influence of all potential adverse events [14,22]. It has been shown that elevated Lp(a) 
on admission is an independent risk factor for subsequent adverse cardiovascular events 
in patients with coronary artery disease [5]. Therefore, laboratory markers to help clini-
cians identify high-risk patients who might have adverse cardiovascular outcomes seem 
important. 
Lp(a) was proven to be associated with coronary severity and worsened clinical out-
comes in patients with different presentations of coronary artery disease [5,6,17]. The 
structure of apo(a) is very similar to that of plasminogen, the plasminogen’s zymogen, 
and the primary clot lysis enzyme. Apo(a) inhibits the binding of plasminogen to C-ter-
minal lysines of the cell surface and extracellular matrix proteins. Lp(a) inhibits fibrinoly-
sis and accumulates in the vascular walls of atherosclerotic lesions. [8]. In a large cohort 
study by Xu et al., Lp(a) was identified as an independent predictor of long-term (> 6 years 
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of follow-up) adverse clinical outcomes, and might aid in risk stratification in patients 
with triple-vessel disease [17]. However, thus far, there are no data confirming the influ-
ence of preoperative elevated Lp(a) on perioperative outcomes after coronary artery by-
pass grafting or valvular and aortic cardiac surgery. 
The first study reporting on the influence of cardiac surgery on Lp(a) levels included 
a cohort of only 20 patients [23] receiving isolated CABG, and reported no information on 
clinical outcomes. To the best of our knowledge, this is the first prospective observational 
cohort study reporting the impact of Lp(a) levels on clinical outcomes after different types 
of cardiac surgery. Our study found that Lp(a) levels did not influence primary or sec-
ondary outcomes in the early postoperative period. In particular, no difference in periop-
erative stroke or myocardial infarction was found for different Lp(a) levels. 
In the BIOSIGNAL study, Arnold et al. reported on the association between elevated 
Lp(a) levels and large-artery atherosclerosis stroke. The group concluded that elevated 
Lp(a) levels were independently associated with stroke aetiology and risk of recurrent 
cerebrovascular events among primarily Caucasian individuals with evident arterioscle-
rotic disease [14]. We found no association between different Lp(a) levels and periopera-
tive stroke; however, the incidence of stroke after the perioperative period was not as-
sessed in the current study period. 
Some evidence shows that elevated Lp(a) stimulates inflammatory pathways, with 
respective pathophysiological responses within a few hours [24]. While a study by Cob-
baert et al. concluded that Lp(a) levels remain constant during CPB in patients undergoing 
isolated CABG [23], we found a significant decrease after CPB in patients with higher 
Lp(a) levels. CPB significantly lowers Lp(a) levels in the initial postoperative period. 
While Lp(a) levels were decreased in all patients following CPB, this decrease was less 
consistent in patients with lower Lp(a) levels, and most evident and significant in patients 
with deep hypothermic circulatory arrest (DHCA) (p = 0.039), followed by operation du-
ration (p = 0.020) and lower body temperature (p = 0.046). No significant correlations were 
observed between duration of CPB support, aortic cross-clamp time, and perfusion sys-
tem used (ECC vs. MiECC). Very recently, a trial reported on successful targeting of in-
creased Lp(a) levels [1]. The potential benefits of this option in cardiac surgery remain to 
be investigated.  
Our study is subject to the limitations of observational research. First, it was a single-
centre study, which limits its external validity. Second, the inclusion of patients was re-
stricted by the operating hours of the institutional biobank; however, since no specific 
policy of patient allocation to the operating room schedule exists at our institution, it 
seems likely that this would have introduced bias. Third, our study categorised partici-
pants according to Lp(a) levels, and did not set distinct cutoff levels, which could have 
reduced its comparability and clinical applicability. Fourth, CPB may lower Lp(a) levels 
by the means of dilution, e.g., through the crystalloid or colloid priming volume; however, 
this effect was likely cancelled out by the last postoperative day. Fifth, only 192 patients 
were eligible, potentially masking possible effects. Furthermore, the measurement of 
Lp(a) levels was limited to the perioperative period; therefore, the reliability and scalabil-
ity of the results we obtained may be limited, and the bivariate relationships illustrated in 
Figure 2 show some nonlinear behaviour—especially for the lowest body temperature—
which warrants caution when examining the results of linear regression. The numbers 
should be considered as approximations of the underlying nonlinear relationships be-
tween these surgical characteristics and the changes in Lp(a) levels. Moreover, it seems 
important to remember that all DHCA patients have controlled core body temperatures 
between 19 and 28 degrees Celsius, which was not considered in the multivariable linear 
regression model. Finally, given the complexity of Lp(a) biology and the enormous chal-
lenge of disentangling cause and effect in the biology of Lp(a), HDL, LDL, triglycerides, 
and other lipids, we focused only on Lp(a). However, this best reflects current therapeutic 
research to selectively target Lp(a) levels with antisense oligonucleotides [8]. The effects 
Cells 2021, 10, 2829 12 of 13 
 
 
of perioperative lipid status on clinical outcomes after cardiac surgery for the same cohort 
are described by Mihalj et al. [25].  
5. Conclusions 
In summary, increased levels of the key metabolite Lp(a) were not associated with 
increased perioperative stroke and/or MACCE rates in patients undergoing coronary, val-
vular, or aortic surgery. The use of CPB was associated with significantly decreased peri-
operative Lp(a) levels No difference in overall mortality was observed in the early post-
operative period, or at one year after surgery, for patients with different Lp(a) levels.  
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4409/10/11/2829/s1: Figure S1: Kernel density distributions of preoperative Lp(a) values (on the log-
scale) and their changes; Table S1: Overview of missing data for the analyses; Table S2: Sensitivity 
analysis of the primary outcomes with regard to the Lp(a) threshold; Table S3: Multivariable linear 
regression of the ratio of postoperative Lp(a) values to preoperative Lp(a) values.  
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